Manufacturers report flumazenil injection shortage
Originally at news.google.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Dentists who use flumazenil to reverse benzodiazepine sedation now face limited supply, raising the risk of delayed or cancelled procedures for patients requiring reversal.
Key points
- ADA News reports an active shortage of flumazenil injection.
- Flumazenil is the standard reversal agent for midazolam, diazepam, and other benzodiazepines used in dental sedation.
- Shortage may affect oral surgeons, periodontists, and general dentists who provide moderate or deep sedation.
- Practices should review alternative sedation protocols or stockpile existing inventory to maintain continuity of care.
Who should care
Read the original on ADA News
Full reporting and any paywall content live on news.google.com. We summarize and score; we do not republish.
Related
- ·Regulatory
Pennsylvania brothers facing 400 years for racketeering conspiracy, $32M Medicaid fraud; RFK Jr. undergoes surgery; GLP-1 users still love chocolate treats - Morning Medical Update
- ·Regulatory
Democrats plan to add vision, hearing, dental to Medicare
- ·Regulatory
FDA warns public about unauthorized direct-to-consumer clear aligners
- ·Regulatory
ADA, CDA collaboration helps protect Proposition 56 dental funding